Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial.
Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung. 2011 Aug; 189(4):261-8.
View in:
PubMed
subject areas
Aged
Bronchodilator Agents
Disease Progression
Female
Forced Expiratory Volume
Gastrointestinal Diseases
Heart Diseases
Humans
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive
Quality of Life
Randomized Controlled Trials as Topic
Respiratory Tract Diseases
Risk
Scopolamine Derivatives
Treatment Outcome